MyMD reports updated Phase 2 data for MYMD-1 in sarcopenia; TNF-α reduction statistically significant at 1050mg

Q/C TECHNOLOGIES, INC.

Cohort 4 (1050mg) showed reduction in TNF-α over 28 days vs placebo (p=0.002 to 0.008).
Phase 2 study met all primary PK and secondary safety/tolerability endpoints across multiple doses.
FDA accepted IND for MYMD-1 in rheumatoid arthritis; Phase 2 trials planned.
Company plans to present clinical safety report to FDA and seek guidance for Phase 3 trial in sarcopenia.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.